Eolas Medical

About Eolas Medical

Eolas Medical is a health technology company that provides a knowledge and communication platform designed for healthcare professionals. The company was founded in 2019 by Dr. Declan Kelly, an emergency medicine physician who experienced firsthand the challenges of accessing critical clinical information at the point of care. The name 'Eolas' is the Irish word for 'knowledge,' reflecting the company's mission to streamline access to medical guidelines, hospital protocols, and medicine information.

The firm operates on a B2B SaaS business model, partnering with hospitals and healthcare organizations through subscription-based licensing. Revenue is generated from annual or monthly subscriptions, with pricing often based on the number of users or level of service. Eolas Medical also offers fees for custom implementation, onboarding, and training services.

The platform serves as a centralized, searchable database accessible via web and mobile apps, replacing traditional intranets and fragmented document stores. Its core features include a repository for clinical guidelines and protocols, a secure in-app messenger for colleagues, and an AI-powered search function that allows clinicians to ask questions in plain language to get answers sourced from their institution's own documents. The system is designed to improve efficiency, reduce the time spent searching for information, and enhance patient safety by ensuring access to the most up-to-date, approved guidance.

The company has achieved significant traction, particularly within the UK's National Health Service (NHS), where it is used by over 80% of acute hospital trusts. As of early 2026, the platform had 200,000 registered users across the UK, US, and Ireland and was utilized in over 400 medical centers globally, including Stanford Hospital and Massachusetts General Hospital. Eolas Medical secured a $12 million Series A funding round in January 2026, led by Acton Capital, to accelerate the rollout of its AI functionality and support international expansion. This followed an earlier seed round in March 2021 and a £2m funding round in 2022.